BMO Capital Markets analysts said the results potentially position lepodisiran as “one of the most durable assets in ...

The stock market—and biotech insiders—reacted negatively to the allegedly forced resignation of CBER Director Peter Marks, ...

BMO Capital analysts view the departure of Dr. Peter Marks from the FDA as a “significant negative” for the biopharma and biotech sectors. The ...

BMO Capital analyst Katja Jancic downgraded U.S. Steel (X) to Market Perform from Outperform with an unchanged price target of $45. The current ...

Small and mid-cap stocks that are high quality have growth-at-a-reasonable price characteristics may present opportunities ...

The value of global syndicated lending declined in the first quarter, according to new data from LSEG Data & Analytics. The ...

BMO Capital Markets upgraded shares of Check Point Software Technologies (NASDAQ:CHKP – Free Report) from a market perform rating to an outperform rating in a research report released on Friday ...

BMO Capital Markets upgraded Check Point Software Technologies (NASDAQ:CHKP) Ltd to Outperform from Market Perform, citing increased confidence in the company’s growth trajectory and a reasonable ...

BMO Capital Markets’ price objective suggests a potential upside of 3.05% from the stock’s previous close. Other equities analysts also recently issued research reports about the stock.